Please assess the completion status of the following clinical trial:

Trial Title: Antiplatelet vs R-tPA for Acute Mild Ischemic Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient age ≥18 years;~2. Study treatment can be started within 4.5h;~3. Ischemic stroke confirmed by head CT or MRI;~4. NIHSS score ≤ 5, and ≤ 1 NIHSS score in single item scores such as vision, language, neglect and single limb and no score in consciousness item;~5. Premorbid mRS ≤ 1;~6. Signed informed consent~Exclusion Criteria:~1. Serious neurological deficits before onset ( mRS ≥ 2)；~2. Obvious head injuries or strokes within 3 months；~3. Subarachnoid hemorrhage;~4. History of intracranial hemorrhage;~5. Intracranial tumor, arteriovenous malformation or aneurysm;~6. Intracranial or spinal cord surgery within 3 months;~7. Arterial puncture at a noncompressible site within the previous seven days;~8. Gastrointestinal or urinary tract hemorrhage within the previous 21 days;~9. Major surgery within 1 month;~10. Systolic pressure ≥180 mmHg or diastolic pressure ≥110 mmHg;~11. Blood glucose \< 50 mg/dl (2.7mmol/L);~12. Heparin therapy or oral anticoagulation therapy within 48 hours;~13. Platelet count of \<100,000/mm3 (This does not need to be verified prior to randomization if clinical abnormality is not suspected);~14. Oral warfarin is being taken and INR\>1.6;~15. Abnormal APTT;~16. Pregnancy;~17. Neurological deficit after epileptic seizures;~18. Myocardial infarction within 3 months;~19. Cerebral infarction with definite anticoagulation indications, such as cerebral infarction caused by cardiogenic embolism;~20. Oral administration is not allowed due to dysphagia;~21. allergy to study drugs;~22. Other serious illness that would confound the clinical outcome at 90 days;~23. Participating in other clinical trials within 3 months;~24. patients not suitable for this clinical studies considered by researcher;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aspirin+ clopidogrel (Type: EXPERIMENTAL): aspirin 100mg qd and clopidogrel 75mg（300mg in the first day）qd with a total of 10-14 days, then oral aspirin 100mg or clopidogrel 75mg qd lasting for 90 days.
- Alteplase (Type: ACTIVE_COMPARATOR): intravenous alteplase (0.9 mg/kg and maximal dose of 90 mg) was given, and followed by antithrombotic protocol 24 hours after thrombolysis based on clinical guideline.

Based on this trial design, predict the completion outcome and termination type (if applicable).